- Home
- LEGH vs PLRX Comparison
LEGH vs PLRX Comparison
Compare LEGH & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- PLRX
- Stock Information
- Founded
- LEGH 2005
- PLRX 2015
- Country
- LEGH United States
- PLRX United States
- Employees
- LEGH N/A
- PLRX N/A
- Industry
- LEGH Homebuilding
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- PLRX Health Care
- Exchange
- LEGH Nasdaq
- PLRX Nasdaq
- Market Cap
- LEGH 588.8M
- PLRX 84.7M
- IPO Year
- LEGH 2018
- PLRX 2020
- Fundamental
- Price
- LEGH $23.97
- PLRX $1.29
- Analyst Decision
- LEGH Strong Buy
- PLRX Hold
- Analyst Count
- LEGH 2
- PLRX 10
- Target Price
- LEGH $29.00
- PLRX $9.79
- AVG Volume (30 Days)
- LEGH 104.8K
- PLRX 1.5M
- Earning Date
- LEGH 08-07-2025
- PLRX 08-06-2025
- Dividend Yield
- LEGH N/A
- PLRX N/A
- EPS Growth
- LEGH 8.04
- PLRX N/A
- EPS
- LEGH 2.29
- PLRX N/A
- Revenue
- LEGH $176,618,000.00
- PLRX N/A
- Revenue This Year
- LEGH N/A
- PLRX N/A
- Revenue Next Year
- LEGH $8.23
- PLRX N/A
- P/E Ratio
- LEGH $10.47
- PLRX N/A
- Revenue Growth
- LEGH N/A
- PLRX N/A
- 52 Week Low
- LEGH $21.58
- PLRX $1.10
- 52 Week High
- LEGH $29.31
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- LEGH 63.30
- PLRX 43.30
- Support Level
- LEGH $21.91
- PLRX $1.13
- Resistance Level
- LEGH $24.17
- PLRX $1.43
- Average True Range (ATR)
- LEGH 0.61
- PLRX 0.11
- MACD
- LEGH 0.27
- PLRX -0.01
- Stochastic Oscillator
- LEGH 89.96
- PLRX 37.57
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.